First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305
posted on 2025-02-03, 16:35authored byAdis Journals on behalf of:, Markus Moehler, Do-Youn Oh, Ken Kato, Tobias Arkenau, Josep Tabernero, Keun-Wook Lee, Sun Young Rha, Hidekazu Hirano, David Spigel, Kensei Yamaguchi, Lucjan Wyrwicz, Umut Disel, Roberto Pazo Cid, Lorenzo Fornaro, Yaling Xu, Tao Sheng, Silu Yang, Alysha Kadva, Marcia Cruz-Correa, Rui-Hua Xu
The article associated with this page has been accepted for online publication and is in the final stages of production. The link to the full text will be made available on this page in the next few days. In the meantime, a pre-typeset version of the article is attached. This is not the final publication and may be subject to some minor changes.